SCAI 2025 - Insights from antiplatelet therapy after transcatheter aortic valve replacement (TAVR) show patients who received single antiplatelet treatment had significantly lower rates of overall six-month mortality, CV death and non-CV death compared to those treated with double antiplatelet treatment.

Dr Francesco Pelliccia (Sapienza University of Rome, Rome, IT) joins us to discuss insights from the TRITAVI registry (NCT03740425) investigating six-month mortality rates from single verses double antiplatelet treatment in patients who have undergone TAVR. TRITAVI collected real-life data from 20 European centres, and these insights reveal outcomes from over 5,500 patients from the registry.

Interview Questions:
1. What is the reasoning behind the TRITAVI registry?
2. What was the study design and patient population?
3. What were the key findings?
4. What are your take-home messages?
5. What further research is needed, and what are the next steps?

Recorded remotely from Rome, 2025.

Editors: Jordan Rance, Yazmin Sadik
Videographers: David-Ben Harosh

Support: This is an independent interview produced by Radcliffe Cardiology.